29 June 2023 : Case report
Endometrial Adenocarcinoma with Discordant Microsatellite Stability Status Treated with First-Line Pembrolizumab: A Case Report and Narrative Review
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare coexistence of disease or pathology
Christopher R. Grant1ABCDEF*, Elaine J. Chiao1EF, Zhaohui L. Arter2ADE, Cary Johnson3C, Truc Tran3BE, Farshid Dayyani2E, Krishnasu Tewari2E, Valery Vilchez4E, Joseph Carmichael 4E, May Cho2ABCDEDOI: 10.12659/AJCR.939448
Am J Case Rep 2023; 24:e939448
Figure 3. Tumor marker trends during use of pembrolizumab.